Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Lymphoma

    Diffuse large B-cell lymphoma (DLBCL)
    Follicular lymphoma (FL)
    Mantle Cell Lymphoma (MCL)

    For optimal search results, please limit to 2 product keywords

    If you are searching for information related to a product:

    • For optimal results, please enter at least 2 search terms in addition to product name
    • Example: [product name] [search term] [search term]
    • Example: Product + clinical trials
    • For an exact match, please include search terms in double quotations. For example: "Elevatum"

      Please enter search terms.

      ASH 2025 Icon

      American Society of Hematology 2025

      December 6-9, 2025

      Orlando, Florida

      Browse agenda
      View Genentech booth map

      Jump to section:

      ASH 2025
      Conference Materials
      Publications
      Clinical Trials
      Disease State Information
      Leukemia Icon

      Leukemia/Myeloid

      EXPLORE
      Rare Blood Disease Icon

      Rare Blood Disorders

      EXPLORE
      TOP

      Genentech Presentations & Posters at ASH 2025 for Lymphoma

      The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings at the ASH conference. To browse full Roche/Genentech congress presentations and posters: Visit Medically.

      Studies titles are abbreviated, click on the presentations and Posters links to view full titles and Content

      Abstract 4486 | Poster

      Pola-R-CHP RWD outcomes

      Dec.7th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 6181 | Poster

      DLBCL & FL time toxicity - full survey results

      Dec.8th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 5352 | Poster

      GO29781: 3L+ FL pivotal cohort 5-yr follow up

      Dec.8th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 6265 | Poster

      RWD of Pola R-CHP (POLARIX) from Flatiron

      Dec.8th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 6179 | Poster

      Patient preferences in R/R DLBCL (full survey results)

      Dec.8th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 5510 | Poster

      NP39488: Glofit-Pola in R/R DLBCL 3-yr follow up

      Dec.8th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 6180 | Poster

      RR FL patient preferences (final readout)

      Dec. 8th l :6:00 PM l Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 5509 | Poster

      SUNMO PROs

      Dec.8th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 2622 | Poster

      Travel burden (DLBCL & FL) - new data cut

      Dec.6th, 2025 | 5:30 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 4489 | Poster

      Health equity disparity (Pola)

      Dec.7th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 2559 | Poster
      a CRL was issued by FDA for this use

      GO41944 (STARGLO): CRS RS update

      Dec.6th, 2025 | 5:30 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 5519 | Poster
      a CRL was issued by FDA for this use

      GO41944 STARGLO 3y FU and 2L

      Dec.8th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 3522 | Poster

      POLARIX DEL MYC/BCL2/BCL6 expression 

      Dec.7th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 49 | Presentation

      POLARIX Molecular Classification

      Dec.6th, 2025 | 9:30 AM | Room: OCCC - Tangerine Ballroom F1

      View Presentation
      Abstract 5329 | Poster

      POLARIX TMTV

      Dec. 8th l 6 PM l Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 1807 | Poster

      MorningSun: 1L LTB FL - longer follow-up

      Dec.6th, 2025 | 5:30 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 62 | Presentation

      MorningSun: 1L DLBCL Elderly/Unfit

      Dec.6th, 2025 | 9:30 AM | Room: OCCC - Tangerine Ballroom F2

      View Presentation
      Abstract 6261 | Poster

      GO29781: CAR-T after Mosun (US case series)

      Dec.8th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 3735 | Poster

      GO40516: Mosun (IV)-Pola in R/R LBCL (Arm J) 3y+ update

      Dec.7th, 2025 | 6:00 PM | Room: OCCC - West Halls B3-B4

      View Poster
      Abstract 3743 | Poster
      a CRL was issued by FDA for this use

      GO41944 STARGLO Subgroups

      Dec.7th, 2025 | 6:00PM | Room: OCCC- West Halls B3-B4

      View Poster
      Abstract 228 | Presentation

      MorningSun: 1L HTB FL - longer follow-up

      Dec.6th, 2025 | 2:00 PM | Room: OCCC - Tangerine Ballroom F2

      View Presentation
      Abstract 5353 | Poster

      GO29781: Mosun SC 3L+ FL pivotal cohort 3-yr follow up

      Dec.8th, 2025 | 6:00 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 1020 | Presentation

      GO40516: Mosun (SC)-Pola in R/R LBCL (Arms L/M) 2y+ update

      Dec.8th, 2025 | 4:30 PM | Room: OCCC - Tangerine Ballroom F1

      View Presentation
      Abstract 1800 | Poster

      CELESTIMO: Arm C (US extension) efficacy/safety and health equity tactics

      Dec.6th, 2025 | 5:30 PM | OCCC - West Halls B3-B4

      View Poster
      Abstract 66 | Presentation

      CO43805: Mosun/Glofit + CelMoD safety, preliminary efficacy, biomarkers

      Dec.6th, 2025 | 9:30 AM | Room: OCCC - Tangerine Ballroom F2

      View Presentation

      The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).

      Publications

      Genentech Publications

      Explore publications for lymphoma by topic.

      View publications

      Clinical Trials

      Explore current clinical trials for lymphoma by enrollment status.

      These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

      Actively Recruiting Trials Ongoing (No Longer Recruiting) Trials
      Glofitamab-gxbm
      Indication Phase Trial Name
      R/R B-cell NHL Phase I/II An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Visit trial
      R/R B-cell NHL Phase I A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma Visit trial
      R/R B-cell NHL Phase I/II A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Visit trial
      R/R MCL Phase III A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma Visit trial
      R/R DLBCL Phase II A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Visit trial
      R/R B-cell NHL Phase I/II A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab(RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab(Gazyva®Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Visit trial
      Mosunetuzumab-axgb
      Indication Phase Trial Name
      1L FL Phase I/II A Phase Ib/II, Open-Label, Multicenter Study With a Non-Randomized Stage Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab Plus Lenalidomide (+Len), and a Randomized Stage Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Patients With Follicular Lymphoma Visit trial
      R/R B-cell NHL Phase I A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma Visit trial
      Englumafusp alfa
      Indication Phase Trial Name
      R/R B-cell NHL Phase I/II An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Visit trial
      P-CD19 x CD20 - ALLO1
      Indication Phase Trial Name
      R/R DLBCL Phase I Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies Visit trial
      Glofitamab-gxbm
      Indication Phase Trial Name
      High-risk DLBCL Phase II A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Visit trial
      DLBCL Phase I A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma Visit trial
      DLBCL Phase III A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Visit trial
      Mosunetuzumab-axgb
      Indication Phase Trial Name
      R/R DLBCL, R/R MCL, R/R FL Phase I/II An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma Visit trial
      R/R FL Phase III Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy Visit trial
      Previously untreated MZL, FL, or DLBCL; R/R RT or tFL Phase II An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies Visit trial
      Polatuzamab Vedotin-piiq
      Indication Phase Trial Name
      Previously untreated MZL, FL, or DLBCL; R/R RT or tFL Phase I/II An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma Visit trial

      Interested in becoming an investigator or have trial questions?

      Reach out to an MSL

      Genentech Past Conferences

      ASH 2024 Genentech Conference Materials

      Review previously released conference materials from ASH 2024

      View ASH 2024 Genentech materials

      The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).

      Disease State Information & Resources

      Webpage

      Bispecific Antibodies

      Bispecific antibodies may play a role in tumor cell apoptosis. Learn more about how they interact with T cells.

      View resource
      Webpage

      CRS

      CRS is a potential serious adverse event of immunotherapies, particularly some T cell–engaging immunotherapies; risk mitigation and early recognition can reduce CRS severity and guide its management.

      View resource

      Products

      COLUMVI

      CD20 x CD3 T-cell engaging bispecific antibody

      View product

      POLIVY

      CD79b-directed antibody and microtubule inhibitor conjugate

      View product

      LUNSUMIO

      CD20 x CD3 T-cell engaging bispecific antibody

      View product

      Looking for more information?

      Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

      Connect with an MSL
      Submit a Request

      Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT

      TOP